In one paragraphArticle in Journal of medical virology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
21 authors.
Maximilian StichHeidelberg University, Medical Faculty Heidelberg, Center for Pediatric and Adolescent Medicine, Department of Pediatrics I, Heidelberg, Germany.ORCID 0000-0002-6237-9058 Vladimir Gonçalves MagalhãesGerman Cancer Research Center (DKFZ), Division Virus-Associated Carcinogenesis, Research Group "Dynamics of Early Viral Infection and the Innate Antiviral Response", Heidelberg, Germany.ORCID 0000-0002-4593-3467 Friederike BürgerHeidelberg University, Medical Faculty Heidelberg, Center for Pediatric and Adolescent Medicine, Department of Pediatrics I, Heidelberg, Germany.
Sven F GarbadeHeidelberg University, Medical Faculty Heidelberg, Center for Pediatric and Adolescent Medicine, Department of Pediatrics I, Heidelberg, Germany.ORCID 0000-0002-7420-4757 Kathrin JeltschHeidelberg University, Medical Faculty Heidelberg, Center for Pediatric and Adolescent Medicine, Department of Pediatrics I, Heidelberg, Germany.ORCID 0000-0002-3658-5691 Kerstin MohrGerman Cancer Research Center (DKFZ), Division Virus-Associated Carcinogenesis, Research Group "Dynamics of Early Viral Infection and the Innate Antiviral Response", Heidelberg, Germany.
Anneke HaddadInstitute for Infection Prevention and Control, University Medical Centre and Faculty of Medicine Freiburg, Freiburg im Breisgau, Germany.ORCID 0000-0003-3429-0475 Roland EllingCenter for Pediatrics and Adolescent Medicine, University Medical Centre and Faculty of Medicine Freiburg, Freiburg im Breisgau, Germany.ORCID 0000-0002-2209-4154 Peter LangUniversity Children's Hospital Tübingen, Department of Hematology/Oncology, Tübingen, Germany.ORCID 0000-0001-7737-2142 Armin RabsteynUniversity Children's Hospital Tübingen, Department of Hematology/Oncology, Tübingen, Germany.ORCID 0000-0002-0553-2693 Eva-Maria JacobsenDepartment of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany.ORCID 0000-0003-4750-0136 Sebastian F N BodeDepartment of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany.ORCID 0000-0001-7217-3312 Barbara MüllerHeidelberg University, Medical Faculty Heidelberg, Department of Infectious Diseases, Virology, Heidelberg, Germany.ORCID 0000-0001-5726-5585 Hans-Georg KräusslichGerman Center for Infection Research (DZIF), Heidelberg Partner Site, Heidelberg, Germany.ORCID 0000-0002-8756-329X Georg Friedrich HoffmannHeidelberg University, Medical Faculty Heidelberg, Center for Pediatric and Adolescent Medicine, Department of Pediatrics I, Heidelberg, Germany.ORCID 0000-0002-6593-896X Jürgen G OkunHeidelberg University, Medical Faculty Heidelberg, Center for Pediatric and Adolescent Medicine, Department of Pediatrics I, Heidelberg, Germany.
Ralf BartenschlagerHeidelberg University, Medical Faculty Heidelberg, Department of Infectious Diseases, Molecular Virology, Heidelberg, Germany.ORCID 0000-0001-5601-9307 Marco BinderGerman Cancer Research Center (DKFZ), Division Virus-Associated Carcinogenesis, Research Group "Dynamics of Early Viral Infection and the Innate Antiviral Response", Heidelberg, Germany.ORCID 0000-0002-5805-6109 Aleš JandaDepartment of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany.ORCID 0000-0001-5604-8378 Hanna RenkUniversity Children's Hospital Tübingen, Department of Pediatric Neurology and Developmental Medicine, Tübingen, Germany.ORCID 0000-0001-7793-0968 Burkhard TönshoffHeidelberg University, Medical Faculty Heidelberg, Center for Pediatric and Adolescent Medicine, Department of Pediatrics I, Heidelberg, Germany.ORCID 0000-0002-6598-6910 Funding
The study was funded by the Ministry of Science, Research and the Arts in Baden-Württemberg, Germany, within the framework of the special funding line for COVID-19 research, part of the measures to combat the SARS-CoV-2 pandemic in the field of medical research. Maximilian Stich was funded by the DZIF clinical leave stipend of the German Center for Infection Research.
6 · The paper itselfAbstract
The pivotal role of the cell entry receptor ACE2 for SARS-CoV-2 infection is well-established. When ACE2 is shed from cell surface into plasma as soluble ACE2 (sACE2), it can effectively neutralize SARS-CoV-2. This longitudinal prospective cohort study analyzed sACE2 activity in 1192 participants, aged 4 months to 81 years, 3 and 12 months after SARS-CoV-2 household exposure. Following SARS-CoV-2 exposure, participants exhibited significantly elevated sACE2 activity, irrespective of confirmed infection, with the highest levels observed in exposed children. Longitudinal analysis revealed a decline in sACE2 levels over time, reaching levels comparable to age- and sex-matched pre-pandemic controls. An increase in sACE2 activity was also confirmed in vitro in Calu-3 (human lung) cells within hours of SARS-CoV-2 exposure, providing a direct link between SARS-CoV-2 exposure and elevated sACE2. This study, therefore, challenges the dichotomy of categorizing SARS-CoV-2 exposed participants as infected or not infected solely on currently established diagnostic assays. It demonstrates lasting host responses independent of B- and T-cell memory and may help to keep SARS-CoV-2 infections in balance and contribute to successful virus clearance in children and adults lacking humoral and cellular immune responses following SARS-CoV-2 exposure. Trial Registration: German Registry for Clinical Studies; Identifier: D 00021521.
Indexed as
Angiotensin-Converting Enzyme 2COVID-19SARS-CoV-2AdolescentAdultAgedAged, 80 and overChildChild, PreschoolFemaleHumansInfantLongitudinal StudiesMaleMiddle AgedProspective StudiesACE2 protein, humanAngiotensin-Converting Enzyme 2ACE2childrenexposurepersistenceSARS‐CoV‐2
Identifiers
PMID39624009
PMCPMC11612704
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390